Leavitt Partners December 1, 2022
Kristin Allen

Leavitt Partners examined publicly available resources to determine the 340B Drug Pricing Program’s (340B) impact on drug prices charged by both covered entities and pharmaceutical manufacturers. To answer these questions, Leavitt Partners undertook a comprehensive literature review of publicly available governmental reports, peer-reviewed journal articles, white papers, news articles, and other publicly available sources to identify the degree to which, and to what...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Govt Agencies, Health System / Hospital, Healthcare System, HHS, Insurance, Medicare, Pharma, Pharma / Biotech, Pricing / Spending, Provider, Survey / Study, Trends
More than half of US adults could benefit from GLP-1 medications, researchers find
RNA editing is the next frontier in gene therapy—here's what you need to know
Rand roadblock: Biotech bill’s uncertain future
How Digital Chemistry Will Improve Cross-Functional Collaboration In The Biopharma Industry
GLP-1 drug coverage for obesity making inroads with large employers: Mercer

Share This Article